Obinutuzumab beta
Phase 3
Obinutuzumab beta is one of 2 therapeutic programs targeting Primary IgA Nephropathy. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
1 competitor in Primary Iga Nephropathy
#DrugCompanyPhaseTrials
1LNP023
NovartisPhase 3
Obinutuzumab beta
CChinese PLA General Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Primary IgA Nephropathy1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Obinutuzumab beta. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- CChinese PLA General Hospital